hbvin4

HBV-IN-4, a derivative of phthalazinone, functions as a potent, orally active inhibitor of HBV DNA replication, exhibiting an IC50 value of 14 nM. It effectively induces the formation of genome-free capsids, demonstrating significant anti-HBV potency[1].

HBV-IN-48, an HBV inhibitor, exhibits potent antiviral activity against HBV in HepDE19 cells, demonstrated by its EC 50 value of 0.005 μM. Additionally, it effectively reduces serum HBV DNA levels in mouse models of HBV infection.

HBV-IN-44 (Compound (S)-2a) is an HBV inhibitor with an IC50 value of 23 nM against HbsAg. It exhibits minimal toxicity in HT22 cells and in the neurite outgrowth of ex vivo mouse DRG neurons.

HBV-IN-45 is a selective and orally bioavailable HBV capsid assembly modulator, with an IC50 of 0.51 μM for HBcAg in HBC cells. [HBV-IN-45] demonstrates potent anti-HBV activity.

HBV-IN-40 (Compound 11826096), with an IC50 of 0.7 µM, serves as a potent HBV inhibitor and exhibits antiviral activity [1].

HBV-IN-41 (compound 45) is a potent, orally active inhibitor of Hepatitis B Virus (HBV) with an EC50 value of 0.027μM [1].

HBV-IN-43 (compound 5832) serves as a potent inhibitor of HBV [1].

HBV-IN-46 (compound 1.6), an active metabolite, acts as an inhibitor of the HBVS antigen, exhibiting an EC50 value of 2.6 nM.

HBV-IN-47 (compound 4a) functions as a capsid assembly modulator with activity against the hepatitis B virus (HBV). It exhibits potent anti-HBV activity in HepAD38 cells and has low toxicity (EC50=0.24 μM). This compound is applicable for research into chronic hepatitis B (CHB).